Results 41 to 50 of about 16,645 (269)

Factors related to inappropriate edoxaban use

Journal of Clinical Pharmacy and Therapeutics, 2019
The aim of this study was to evaluate the appropriateness and clinical outcomes of edoxaban use, and to determine the role of clinical pharmacists in improving the efficacy and safety of edoxaban use.A retrospective study was performed by using an electronic medical record and anticoagulation clinical data from 600 patients who received edoxaban from 1
Bo Min Jang, Ok Sang Lee, Eun Jeong Shin, Eun Jeong Cho, Sung Yeon Suh, Yoon Sook Cho, Myung Koo Lee, Sandy Jeong Rhie   +7 more
openalex   +4 more sources

Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial‐mesenchymal transition and inflammatory response

Physiological Reports, 2022
Chronic kidney disease (CKD) is an increasing and life‐threatening disease worldwide. Recent evidence indicates that blood coagulation factors promote renal dysfunction in CKD patients.
Lixin Fang, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Hiroshi Kawanishi, Tomonobu Takikawa, Yuta Ozaki, Kunihiko Takahara, Minako Tatsumi, Mikito Takefuji, Toyoaki Murohara, Noriyuki Ouchi   +11 more
doaj   +1 more source

NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]

, 2016
Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne, Hicks, Tim, Stewart, Fiona   +2 more
core   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation:systematic review, network meta-analysis and cost-effectiveness analysis [PDF]

, 2017
BACKGROUND: Warfarin is effective for stroke prevention in atrial fibrillation (AF), but anticoagulation is underused in clinical care. The risk of venous thromboembolic disease during hospitalisation can be reduced by low-molecular-weight heparin (LMWH):
Sterne, Jonathan Ac, Bodalia, Pritesh N, Bryden, Peter A, Davies, Philippa A, López-López, Jose A, Okoli, George N, Thom, Howard Hz, Caldwell, Deborah M, Dias, Sofia, Eaton, Diane, Higgins, Julian Pt, Hollingworth, William, Salisbury, Chris, Savović, Jelena, Sofat, Reecha, Stephens-Boal, Annya, Welton, Nicky J, Hingorani, Aroon D   +17 more
core   +3 more sources

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults [PDF]

Clinical Drug Investigation, 2015
The oral direct factor Xa inhibitor edoxaban is a P-glycoprotein (P-gp) substrate metabolized via carboxylesterase-1 and cytochrome P450 (CYP) 3A4/5. The effect of rifampin-induced induction of P-gp and CYP3A4/5 on transport and metabolism of edoxaban through the CYP3A4/5 pathway was investigated in a single-dose edoxaban study.This was a phase 1, open-
Dolly A. Parasramupria, Jeanne Mendell, Ling He, Madhuri Desai, Shuquan Chen   +4 more
core   +5 more sources

State of play and future direction with NOACs: An expert consensus. [PDF]

, 2018
Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events ...
A.J. Camm, A.T. Cohen, Ageno, Agnelli, Alings, Ansell, Ansell, Apostolakis, Avgil-Tsadok, Beyer-Westendorf, Beyer-Westendorf, Beyer-Westendorf, Bohula, Bouillon, Brunner-Ziegler, Caldeira, Caldeira, Camm, Cannon, Cohen, Cohen, Coleman, Connolly, Connolly, Connolly, Cronin-Fenton, De Caterina, De Caterina, De Caterina, De Caterina, Diener, Diener, Diener, Douketis, Easton, Eikelboom, Ensor, F. Verheugt, Fang, Fauchier, Forslund, Fox, Friberg, Friberg, Furugohri, G. Agnelli, G.Y. Lip, Gage, Gibson, Giugliano, Glund, Granger, Gross, Guo, H. Heidbuchel, Hankey, Heidbuchel, Heidbuchel, Heit, Heit, Hijazi, Hohnloser, Husted, Investigators, J.L. Zamorano, Kearon, Keeling, Khorana, Kirchhof, Kooiman, Kooistra, Larsen, Levy, Lip, Lip, Lip, Lip, Lip, Lublóy, Martinez, Masjuan, Mendell, Mendell, Miyasaka, Moore, Morgan, Mungall, Murphy, Márquez-Contreras, Nielsen, Oldgren, Paciaroni, Paciaroni, Patel, Perzborn, Peterson, Pinto, Pollack, Pollack, Price, Prins, Proietti, Proietti, R. De Caterina, Raskob, Renda, Roffi, Roldán, Ruff, Ruff, Sandén, Sardar, Sardar, Sarich, Schulman, Schulman, Senoo, Senoo, Shekelle, Sjögren, Song, Stacy, Stampfuss, Stangier, Steinberg, Tafur, The EINSTEIN investigators, The EINSTEIN–PE Investigators, van der Hulle, van Walraven, Verhamme, Vrijens, Watanabe, Weitz, Wolf, Zamorano   +135 more
core   +4 more sources

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database

BDJ Open, 2023
Introduction Literature reviews support continuing anticoagulation during dental procedures. However, studies often present grouped anticoagulation data, and information on individual anticoagulant management would be helpful to dentists.
Cathy Chen, Manish Saxena, Christian von Heymann, Thomas Vanassche, James Jin, Robert Lersch, Sabine Köhler, Amparo Santamaria, Martin Unverdorben, Paolo Colonna   +9 more
doaj   +1 more source

A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation

Frontiers in Physiology, 2018
Background: Non-vitamin K antagonist oral anticoagulants (NOACs) depend on some degree of renal excretion, and no head-to-head comparisons based on renal function is available. This study mainly investigated the trade-off property of NOACs in nonvalvular
Ling-Yun Zhou, Shuo-Fei Yang, Zhen Zhang, Chi Zhang, Long Shen, Zhi-Chun Gu, Xiao-Cong Zuo   +6 more
doaj   +1 more source

Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial

Journal of Arrhythmia, 2021
Background Nonadherence diminishes the efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF). This report presents the baseline survey results regarding medication adherence among NVAF patients who were ...
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada, Nobuhisa Hagiwara, the SMAAP‐AF investigators   +11 more
doaj   +1 more source